Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort

Por Regnault, Antoine, Boroojerdi, Babak, Meunier, Juliette, Bani, Massimo, Morel, Thomas, Cano, Stefan
Publicado no J Neurol (2019)

Genotype over-diagnosis in amygdala responsiveness: affective processing in social anxiety disorder

Por Furmark, Tomas, Henningsson, Susanne, Appel, Lieuwe, Åhs, Fredrik, Linnman, Clas, Pissiota, Anna, Faria, Vanda, Oreland, Lars, Bani, Massimo, Pich, Emilio Merlo, Eriksson, Elias, Fredrikson, Mats
Publicado em 2009

Amygdala Subregions Tied to SSRI and Placebo Response in Patients with Social Anxiety Disorder

Por Faria, Vanda, Appel, Lieuwe, Åhs, Fredrik, Linnman, Clas, Pissiota, Anna, Frans, Örjan, Bani, Massimo, Bettica, Paolo, Pich, Emilio M, Jacobsson, Eva, Wahlstedt, Kurt, Fredrikson, Mats, Furmark, Tomas
Publicado em 2012

Occupancy of Brain Dopamine D(3) Receptors and Drug Craving: A Translational Approach

Por Mugnaini, Manolo, Iavarone, Laura, Cavallini, Palmina, Griffante, Cristiana, Oliosi, Beatrice, Savoia, Chiara, Beaver, John, Rabiner, Eugenii A, Micheli, Fabrizio, Heidbreder, Christian, Andorn, Anne, Merlo Pich, Emilio, Bani, Massimo
Publicado em 2013

In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism

Por Erritzoe, David, Tziortzi, Andri, Bargiela, David, Colasanti, Alessandro, Searle, Graham E, Gunn, Roger N, Beaver, John D, Waldman, Adam, Nutt, David J, Bani, Massimo, Merlo-Pich, Emilio, Rabiner, Eugenii A, Lingford-Hughes, Anne
Publicado em 2014

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis

Por Conrado, Daniela J., Nicholas, Timothy, Tsai, Kuenhi, Macha, Sreeraj, Sinha, Vikram, Stone, Julie, Corrigan, Brian, Bani, Massimo, Muglia, Pierandrea, Watson, Ian A., Kern, Volker D., Sheveleva, Elena, Marek, Kenneth, Stephenson, Diane T., Romero, Klaus
Publicado no Clin Transl Sci (2017)

A Selective Neurokinin-1 Receptor Antagonist in Chronic PTSD: a Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial

Por Mathew, Sanjay J., Vythilingam, Meena, Murrough, James W., Zarate, Carlos A., Feder, Adriana, Luckenbaugh, David A., Kinkead, Becky, Parides, Michael K., Trist, David G., Bani, Massimo S., Bettica, Paolo U., Ratti, Emiliangelo M., Charney, Dennis S.
Publicado em 2010

A Link between Serotonin-Related Gene Polymorphisms, Amygdala Activity, and Placebo-Induced Relief from Social Anxiety

Por Furmark, Tomas, Appel, Lieuwe, Henningsson, Susanne, Åhs, Fredrik, Faria, Vanda, Linnman, Clas, Pissiota, Anna, Frans, Örjan, Bani, Massimo, Bettica, Paolo, Pich, Emilio Merlo, Jacobsson, Eva, Wahlstedt, Kurt, Oreland, Lars, Långström, Bengt, Eriksson, Elias, Fredrikson, Mats
Publicado no J Neurosci (2008)

Development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson’s disease to inform clinical trial designs

Por Ahamadi, Malidi, Conrado, Daniela J, Macha, Sreeraj, Sinha, Vikram, Stone, Julie, Burton, Jackson, Nicholas, Timothy, Gallagher, Jill, Dexter, David, Bani, Massimo, Boroojerdi, Babak, Smit, Hans, Weidemann, Jonas, Chen, Chao, Yang, Minhua, Maciuca, Romeo, Lawson, Rachael, Burn, David, Marek, Kenneth, Venuto, Charles, Stafford, Bob, Akalu, Mussie, Stephenson, Diane, Romero, Klaus
Publicado no Clin Pharmacol Ther (2019)